logo-loader
Futura Medical PLC

Director/PDMR Shareholding

/**/ link{ color: blue }visited{ color: purple } .aq{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.aq{}p.dr{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 12.1pt; text-align: justify}span.dp{font-size:14.0pt;color:black}p.ds{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:12.1pt;text-align:justify;line-height: normal}span.dn{color:black}table.dt{width:456.05pt}tr.de{height:80.8pt}td.dk{width:49.65pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm;height:80.8pt}p.du{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 12.1pt} td.di{width:63.75pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm;height:80.8pt}p.dv{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 12.1pt; text-align: right}td.dh{width:125.95pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm;height:80.8pt}td.dg{width:83.95pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm;height:80.8pt}td.df{width:83.1pt;border:none;border-bottom: solid windowtext 1.0pt;padding:0cm 0cm 0cm 0cm;height:80.8pt}tr.cw{height:13.2pt}td.dc{width:49.65pt;padding:0cm 0cm 0cm 0cm; height:13.2pt}p.dw{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:12.1pt;line-height:11.75pt}td.da{width:63.75pt;padding:0cm 0cm 0cm 0cm; height:13.2pt}p.dx{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: 11.75pt; margin-bottom: 12.1pt; text-align: right} td.cz{width:125.95pt;padding:0cm 0cm 0cm 0cm; height:13.2pt}td.cy{width:83.95pt;padding:0cm 0cm 0cm 0cm; height:13.2pt}td.cx{width:83.1pt;padding:0cm 0cm 0cm 0cm; height:13.2pt}tr.co{height:27.2pt}td.cu{width:49.65pt;padding:0cm 0cm 0cm 0cm; height:27.2pt}p.dy{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:12.1pt;line-height:normal}td.cs{width:63.75pt;padding:0cm 0cm 0cm 0cm; height:27.2pt}p.dz{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 12.1pt; text-align: right}td.cr{width:125.95pt;padding:0cm 0cm 0cm 0cm; height:27.2pt}td.cq{width:83.95pt;padding:0cm 0cm 0cm 0cm; height:27.2pt} td.cp{width:83.1pt;padding:0cm 0cm 0cm 0cm; height:27.2pt}tr.ci{height:13.95pt}td.cn{width:49.65pt;padding:0cm 0cm 0cm 0cm; height:13.95pt}td.cm{width:63.75pt;padding:0cm 0cm 0cm 0cm; height:13.95pt}td.cl{width:125.95pt;padding:0cm 0cm 0cm 0cm; height:13.95pt}td.ck{width:83.95pt;padding:0cm 0cm 0cm 0cm; height:13.95pt}td.cj{width:83.1pt;padding:0cm 0cm 0cm 0cm; height:13.95pt}tr.cc{height:26.4pt}td.ch{width:49.65pt;padding:0cm 0cm 0cm 0cm; height:26.4pt}td.cg{width:63.75pt;padding:0cm 0cm 0cm 0cm; height:26.4pt} td.cf{width:125.95pt;padding:0cm 0cm 0cm 0cm; height:26.4pt}td.ce{width:83.95pt;padding:0cm 0cm 0cm 0cm; height:26.4pt}td.cd{width:83.1pt;padding:0cm 0cm 0cm 0cm; height:26.4pt}p.ea{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:12.1pt;text-align:justify;line-height: 11.75pt;background:white}p.eb{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif"; line-height: normal; margin-bottom: 0cm; text-align: center}p.ec{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 12.65pt; margin-bottom: 12.1pt}p.ed{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 0cm}p.ee{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt}p.ef{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:12.1pt;line-height:12.65pt}p.eg{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 0cm; text-align: justify} p.eh{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify}span.bs{color: windowtext;text-decoration:none}p.g,li.g,div.g{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";}p.ei{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold}p.ej{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 12.65pt; margin-bottom: 12.1pt; text-align: justify}table.ek{width:444.05pt;margin-left:-8.0pt;border-collapse:collapse}td.bo{width:11.8pt;border:solid black 1.0pt; padding:1.2pt 1.2pt 1.2pt 3.0pt}p.el{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 15.6pt; margin-bottom: 12.1pt; margin-left: 0cm; margin-right: 0cm; margin-top: 2.4pt}td.bn{width:423.85pt;border:solid black 1.0pt; border-left:none;padding:1.2pt 1.2pt 1.2pt 3.0pt}td.bl{width:11.8pt;border:solid black 1.0pt; border-top:none;padding:1.2pt 1.2pt 1.2pt 3.0pt} p.em{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:2.4pt;margin-right:0cm;margin-bottom: 12.1pt;margin-left:0cm;line-height:15.6pt}td.bk{width:142.6pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:1.2pt 1.2pt 1.2pt 3.0pt}td.bj{width:277.05pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:1.2pt 1.2pt 1.2pt 3.0pt}td.bi{width:423.85pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:1.2pt 1.2pt 1.2pt 3.0pt}p.en{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:12.1pt;line-height:15.6pt}p.eo{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:12.1pt;line-height:12.0pt}table.ep{width:139.1pt;border-collapse:collapse}td.be{width:94.6pt;border:solid black 1.0pt; padding:1.2pt 1.2pt 1.2pt 3.0pt}p.eq{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: 12.0pt; margin-bottom: 12.1pt; margin-left: 0cm; margin-right: 7.8pt; margin-top: 0cm; text-align: center}td.bd{width:72.35pt;border:solid black 1.0pt; border-left:none;padding:1.2pt 1.2pt 1.2pt 3.0pt} td.bc{width:94.6pt;border:solid black 1.0pt; border-top:none;padding:1.2pt 1.2pt 1.2pt 3.0pt}td.bb{width:72.35pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:1.2pt 1.2pt 1.2pt 3.0pt}p.er{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 12.1pt; text-align: center}table.es{width:445.05pt;margin-left:-9.0pt;border-collapse:collapse}td.ax{width:424.85pt;border:solid black 1.0pt; border-left:none;padding:1.2pt 1.2pt 1.2pt 3.0pt}td.aw{width:142.65pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:1.2pt 1.2pt 1.2pt 3.0pt}td.av{width:278.0pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:1.2pt 1.2pt 1.2pt 3.0pt}td.au{width:424.85pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:1.2pt 1.2pt 1.2pt 3.0pt}p.et{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 12.1pt}p.eu{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 15.6pt; margin-bottom: 12.1pt; margin-left: 0cm; margin-right: 7.8pt; margin-top: 2.4pt; text-align: center} p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";} /**/
RNS Number : 8723M
Futura Medical PLC
18 September 2019
 

Directors' / PDMR Dealing and Grant of Options

18 September 2019

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology currently focused on sexual health and pain, today announces that on 17 September 2019 it made its annual grant of options over a total of 1,400,000 ordinary shares of 0.2p each in the Company ("Ordinary Shares") to employees and Directors, of which 650,000 options were granted to Directors and PDMRs as detailed below.

Director

Number
of options
granted

Exercise
price

Exercise period

Total number
of options
held following
notification

Total number
of Ordinary
Shares held







J H Barder

250,000

31p

1 Oct 2021 - 30 Sep 2026

1,750,000

1,085,972







A Hildreth

200,000

31p

1 Oct 2021 - 30 Sept 2026

400,000

142,857







K W James

200,000

31p

1 Oct 2021 - 30 Sept 2026

800,000

299,581

 

Of the total 1,400,000 options, 1,281,935 were granted under the Futura Medical plc Enterprise Management Incentive Scheme, and 118,065 were granted under the unapproved scheme.

The main vesting condition of the options is that the Director/PDMR/employee remains employed with the Company as at the date of exercise.  Further disclosures are contained in the tables below. 

 ENDS

 

For further information please contact:

Futura Medical plc 
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO

Email: [email protected]
Tel: +44 (0) 1483 685 670

Nominated Adviser and Broker:
Liberum
Bidhi Bhoma/ Euan Brown/ Kane Collings
Tel: +44 (0) 203 100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: [email protected]

Tel: +44 (0) 203 950 9144

 

Notes to editors

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with a 450 patient open label extension.  FM57 is progressing on track, with headline data expected by the end of 2019.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

James Barder

2

Reason for the notification

a)

Position/status

Chief Executive Officer

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Futura Medical plc

b)

LEI

21380053QLT46UNV2303

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of 0.2 pence each

 

 

GB0033278473

b)

Nature of the transaction

Grant of options over Ordinary Shares

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

Exercise price of
31 pence

 

250,000

 

 

d)

Aggregated information

-         Aggregated volume

-         Price

N/A single transaction

e)

Date of the transaction

17 September 2019

f)

Place of the transaction

Outside a trading venue

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Angela Hildreth

2

Reason for the notification

a)

Position/status

Finance Director and
Chief Operating Officer

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Futura Medical plc

b)

LEI

21380053QLT46UNV2303

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of 0.2 pence each

 

 

GB0033278473

b)

Nature of the transaction

Grant of options over Ordinary Shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

Exercise price of
31
 pence

200,000

 

d)

Aggregated information

-         Aggregated volume

-         Price

N/A single transaction

e)

Date of the transaction

17 September 2019

f)

Place of the transaction

Outside a trading venue

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Ken James

2

Reason for the notification

a)

Position/status

Executive Director
and Head of R&D

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Futura Medical plc

b)

LEI

21380053QLT46UNV2303

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of 0.2 pence each

 

 

GB0033278473

b)

Nature of the transaction

Grant of options over Ordinary Shares

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

Exercise price of
31
 pence

200,000

 

d)

Aggregated information

-         Aggregated volume

-         Price

N/A single transaction

e)

Date of the transaction

17 September 2019

f)

Place of the transaction

Outside a trading venue

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHLLFSRALITLIA

Quick facts: Futura Medical PLC

Price: 30.275

Market: AIM
Market Cap: £61.96 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Block Energy completes critical phase of WR-38Z sidetrack

Headlines from Proactive UK newsroom. Block Energy (LON:BLOE) has completed a critical phase of the sidetrack programme at its WR-38Z well on the West Rustavi field in Georgia. New casing has been cemented through the build section of the well, which will prevent fluid incursion into the...

on 21/10/19

RNS

Holding(s) in Company

2 hours, 1 minute ago

Holding(s) in Company

1 day, 21 hours ago

Holding(s) in Company

1 day, 21 hours ago

Holding(s) in Company

1 week, 4 days ago

Holding(s) in Company

3 weeks, 3 days ago

Change of Auditor

on 23/10/19